EDWARDS LIFESCIENCES CORPORATION (EW)
Healthcare › Orthopedic, Prosthetic & Surgical Appliances & Supplies
Price History
Feb 9, 2026 — Apr 4, 2026Investment Snapshot
- Trading 174% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 6/9 — moderate financial health
- ROE of 13.2% — below-average profitability
- Revenue growing at 12% annually
EDWARDS LIFESCIENCES CORPORATION (EW) is a Healthcare company operating in Orthopedic, Prosthetic & Surgical Appliances & Supplies, listed on the NYSE , with a market capitalisation of $48.9 billion . Key value metrics: P/E ratio 35.8, P/B ratio 4.73, Piotroski F-Score 6 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
EDWARDS LIFESCIENCES CORPORATION — Fundamental Analysis Summary
EDWARDS LIFESCIENCES CORPORATION (EW) is currently trading 174% above its Graham Number of $30.71, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries an elevated trailing P/E ratio of 35.8x.
On financial health, EW shows a moderate Piotroski F-Score of 6/9, and modest return on equity of 13.2% (sector average: -19.8%), and minimal leverage with a debt-to-equity ratio of 0.06.
StockPik's composite Value Score for EW is 64/100 — an above-average value rating. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
EW reports a high gross margin of 78.2% (sector average: 33.5%) and a strong operating margin of 24.9%.
EW shows revenue growing at 12% year-over-year, with earnings declining at 74%.